Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy
Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy
Active, not recruiting · NCT03315364 · Registry updated 2026-04-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy | Disease Attributes, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 / Phase 3 | 2026-04-01 | NCT03315364 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Daehwa Pharmaceutical Co., Ltd. | 1 |
51 results · Page 1 of 3
Research sites
Swipe the table sideways for more columns.